Although our genetic perturbation of FAM126B in FAM126Alow CRC cell lines and cell line-derived xenograft models demonstrated antitumor activity of FAM126B targeting, two issues need to be resolved in order to translate our findings into clinical testing. Here, HYCC2 is linked to colorectal carcinoma.